» Articles » PMID: 17262741

Results Following Resection for Stage IV Gastric Cancer; Are Better Outcomes Observed in Selected Patient Subgroups?

Overview
Journal J Surg Oncol
Date 2007 Jan 31
PMID 17262741
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients who present with stage IV gastric cancer are not commonly managed with surgical resection as effective palliation can usually be accomplished with systemic chemotherapy, endoscopic stenting, or surgical bypass procedures. Given the inherent morbidity and mortality associated with gastrectomy, palliative resection for stage IV gastric cancer should be reserved for ideal surgical candidates who are most likely to benefit from the procedure. The purpose of this study is to review outcomes following resection for stage IV gastric cancer, and to identify criteria predictive of improved outcomes following gastrectomy in this setting.

Methods: A retrospective review of a prospective GI oncology database was conducted. Sixty-three patients with stage IV gastric cancer managed with surgical resection between 1989 and 2001 were identified. Variables including demographic data, patterns of distant spread (ex: peritoneal, lymphatic, hematogenous), location of tumor, and type of gastrectomy were utilized to conduct survival analyses.

Results: Actuarial survival for all patients at one and 3-year intervals was 52% and 12%, respectively. Improved survival was observed for patients of East Asian race (median survival 20 vs. 12 months, P < 0.05, students t-test) and age less than 60 years (median survival 15 vs. 12 months, P < 0.05). This trend was also illustrated by Kaplan-Meier survival analysis. Other variables including pattern of distant spread, location of tumor, and type of gastrectomy were not associated with a significant difference in survival. Both East Asian race and age less than 60 years were statistically significant predictors of improved survival when assessed by univariate regression analysis. When variables were analyzed in a multivariate regression analysis, Asian race and age <60 both lost their statistical significance as independent predictors of improved survival.

Conclusions: Long-term survival for patients with stage IV gastric cancer who are managed with surgical resection is achievable. Patient specific variables including East Asian race and age less than 60 years appear to be associated with prolonged survival when assessed by comparison of means, Kaplan-Meier analysis, and univariate regression analysis. However, multivariate regression analysis failed to demonstrate these factors as independent predictors of improved outcome. In conclusion, highly selected acceptable risk surgical candidates with stage IV gastric cancer should be considered for management with surgical resection in clinically appropriate scenarios.

Citing Articles

Current standards of surgical management of gastric cancer: an appraisal.

Magyar C, Rai A, Aigner K, Jamadar P, Tsui T, Gloor B Langenbecks Arch Surg. 2023; 408(1):78.

PMID: 36745231 DOI: 10.1007/s00423-023-02789-5.


The benefits of surgery plus extensive intraoperative peritoneal lavage (EIPL) for patients with gastric cancer compared with surgery alone: a systematic review and meta-analysis.

Li S, Li L, Tan B, Wang J, Xue S Updates Surg. 2021; 74(1):65-72.

PMID: 34170498 DOI: 10.1007/s13304-021-01120-5.


Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis.

Cowling J, Gorman B, Riaz A, Bundred J, Kamarajah S, Evans R J Gastrointest Cancer. 2020; 52(1):41-56.

PMID: 32959118 PMC: 7900337. DOI: 10.1007/s12029-020-00519-4.


Evaluation of pharmacological therapies used in Costa Rica in patients with metastatic gastric cancer: a retrospective study.

Cordero-Garcia E, Ramos-Esquivel A, Alpizar-Alpizar W J Gastrointest Oncol. 2019; 10(3):523-528.

PMID: 31183203 PMC: 6534705. DOI: 10.21037/jgo.2019.01.18.


Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study.

Li W, Jiang H, Yu Y, Wang Y, Wang Z, Cui Y Cancer Manag Res. 2019; 11:2007-2013.

PMID: 30881125 PMC: 6407509. DOI: 10.2147/CMAR.S192570.